Glaukos Corporation (GKOS): Price and Financial Metrics
GKOS Price/Volume Stats
Current price | $85.45 | 52-week high | $97.24 |
Prev. close | $85.49 | 52-week low | $45.38 |
Day low | $85.04 | Volume | 343,200 |
Day high | $87.08 | Avg. volume | 739,928 |
50-day MA | $90.07 | Dividend yield | N/A |
200-day MA | $75.69 | Market Cap | 4.23B |
GKOS Stock Price Chart Interactive Chart >
GKOS POWR Grades
- GKOS scores best on the Quality dimension, with a Quality rank ahead of 54.22% of US stocks.
- The strongest trend for GKOS is in Growth, which has been heading down over the past 26 weeks.
- GKOS's current lowest rank is in the Momentum metric (where it is better than 4.37% of US stocks).
GKOS Stock Summary
- GKOS has a higher market value than 69.71% of US stocks; more precisely, its current market capitalization is $3,728,287,988.
- With a price/sales ratio of 12.28, GLAUKOS CORP has a higher such ratio than 91.05% of stocks in our set.
- Over the past twelve months, GKOS has reported earnings growth of 51.2%, putting it ahead of 82.35% of US stocks in our set.
- Stocks that are quantitatively similar to GKOS, based on their financial statements, market capitalization, and price volatility, are DMRC, GPRO, KOPN, HYPR, and RFL.
- Visit GKOS's SEC page to see the company's official filings. To visit the company's web site, go to www.glaukos.com.
GKOS Valuation Summary
- In comparison to the median Healthcare stock, GKOS's price/earnings ratio is 202.92% lower, now standing at -30.
- Over the past 104 months, GKOS's price/sales ratio has gone down 6.4.
Below are key valuation metrics over time for GKOS.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
GKOS | 2023-12-29 | 12.8 | 8.1 | -30.0 | -36.2 |
GKOS | 2023-12-28 | 12.9 | 8.2 | -30.3 | -36.6 |
GKOS | 2023-12-27 | 12.9 | 8.2 | -30.4 | -36.6 |
GKOS | 2023-12-26 | 12.8 | 8.2 | -30.1 | -36.3 |
GKOS | 2023-12-22 | 13.2 | 8.4 | -31.1 | -37.4 |
GKOS | 2023-12-21 | 13.7 | 8.7 | -32.1 | -38.6 |
GKOS Growth Metrics
- The 3 year revenue growth rate now stands at 50.5%.
- Its 5 year revenue growth rate is now at 87.32%.
- The 3 year net income to common stockholders growth rate now stands at -139.57%.
The table below shows GKOS's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 284.875 | -33.598 | -89.607 |
2022-06-30 | 288.316 | 10.707 | -55.801 |
2022-03-31 | 293.724 | 30.304 | -27.747 |
2021-12-31 | 294.011 | 24.708 | -49.593 |
2021-09-30 | 294.005 | 39.963 | -38.369 |
2021-06-30 | 284.126 | 12.603 | -60.347 |
GKOS's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- GKOS has a Quality Grade of C, ranking ahead of 54.76% of graded US stocks.
- GKOS's asset turnover comes in at 0.279 -- ranking 135th of 186 Medical Equipment stocks.
- FONR, ATRC, and BSX are the stocks whose asset turnover ratios are most correlated with GKOS.
The table below shows GKOS's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.279 | 0.747 | -0.076 |
2021-03-31 | 0.236 | 0.681 | -0.129 |
2020-12-31 | 0.238 | 0.592 | -0.218 |
2020-09-30 | 0.243 | 0.595 | -0.310 |
2020-06-30 | 0.291 | 0.632 | -0.400 |
2020-03-31 | 0.432 | 0.731 | -0.328 |
Glaukos Corporation (GKOS) Company Bio
Glaukos Corporation develops and commercializes products and procedures designed for the treatment of glaucoma. The company was founded in 1998 and is based in Laguna Hills, California.
Latest GKOS News From Around the Web
Below are the latest news stories about GLAUKOS CORP that investors may wish to consider to help them evaluate GKOS as an investment opportunity.
Glaukos Corp President & COO Joseph Gilliam Sells 25,000 SharesJoseph Gilliam, President & COO of Glaukos Corp (NYSE:GKOS), executed a sale of 25,000 shares in the company on December 21, 2023, according to a SEC Filing. |
Glaukos Announces Participation in the J.P. Morgan Healthcare ConferenceALISO VIEJO, Calif., December 20, 2023--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 5:15 p.m. PT in San Francisco, CA. |
Glaukos' (GKOS) iDose TR Gets FDA Nod for Glaucoma TreatmentThe FDA approval of Glaukos' (GKOS) iDose TR is likely to reshape glaucoma care. A micro-invasive breakthrough promises proactive, durable treatment, heralding a new era in eye health. |
Glaukos (GKOS) Hits 52-Week High: What's Aiding the Stock?Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent. |
Glaukos wins FDA approval for drug-releasing eye implant to treat glaucomaWilliam Blair analysts said the product “should revolutionize how glaucoma is treated by addressing noncompliance with drops.” |
GKOS Price Returns
1-mo | -7.75% |
3-mo | 7.35% |
6-mo | 13.55% |
1-year | 76.04% |
3-year | -3.37% |
5-year | 6.10% |
YTD | 7.50% |
2023 | 81.98% |
2022 | -1.71% |
2021 | -40.95% |
2020 | 38.17% |
2019 | -3.03% |
Continue Researching GKOS
Want to do more research on GLAUKOS Corp's stock and its price? Try the links below:GLAUKOS Corp (GKOS) Stock Price | Nasdaq
GLAUKOS Corp (GKOS) Stock Quote, History and News - Yahoo Finance
GLAUKOS Corp (GKOS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...